![]() Ranbaxy launches Soliten for treatment of urology disorderPublished on Sat, Aug 19, 2006 at 11:13 | Source : Moneycontrol.com Updated at Sat, Aug 19, 2006 at 13:59
Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of its brand Commenting on the launch, Sanjeev I. Dani, Regional Director, India & Middle East, Ranbaxy, said, "An overactive bladder largely remains untreated due to prevailing low awareness amongst its sufferers. The introduction of Speaking on the launch of Soliten, Dr Gopal Badlani, a leading Urologist from the Long Island Jewish Medical Centre, USA, said, " Solifenacin is a relatively new drug and has been present in the US for around 2 years. The drug has exhibited certain unique advantages over the current available therapy, which makes it different and an interesting new agent for the treatment of OAB with predominant urgency, a common ailment. It is being introduced in India soon after the international launch and will lead to significant improvement in the quality of life of patients suffering from the disease ." One out of every eleven individuals in the above 40 age group is believed to suffer from an Overactive Bladder. The problem is equally common in males as well as females and more dominant among the urban population. Ranbaxy Laboratories Limited, headquartered in Sourced From: Ranbaxy Laboratories Ltd
PREVIOUS STORY Trending NewsBusiness News
|
NewsVideos
Interviews
May 27 2012, 11:52 | Source: CNBC-TV18 ![]() May 27 2012, 11:00 | Source: CNBC-TV18 ![]() Subscribe to Moneycontrol Newsletters |
|||||||